Allinaire Therapeutics

Allinaire Therapeutics is developing novel therapies for cardiopulmonary diseases, including a humanized anti-Endothelial Monocyte-Activating Polypeptide II (EMAP II) monoclonal antibody, which is currently being developed as a potential disease-modifying therapy for PAH.